Our proprietary approach - TM Widely-Targeted Metabolomics is the combination of untargeted metabolite profiling followed by the accurate (relative) quantification of the identified metabolites. It is used for human and animal samples analysis, and as such, it is mainly used for biomedical research. In the meantime, we have examples of its successful application in agri-food area too: with seafood and livestock samples. The curated database contains 280,000 metabolites, which includes 3000 metabolites not found in public databases, allowing for more annotations from high-resolution mass spec data. We have studied human and animal samples, including plasma, serum, feces, and a variety of tissues (liver, kidney, intestine, brain, placenta, etc.). In animal and human samples Widely-Targeted Metabolomics identifies on average 1800 metabolites in plasma or serum samples, 2000 metabolites in fecal samples, and 1800 metabolites in tissue samples. To learn more about Widely-Targeted Metabolomics technology check the last issue of MetaboNews (page 11-17).
As lipids play a vital role in biological systems and processes, we offer Quantitative Lipidomics as a high-throughput targeted approach that simultaneously identifies and quantifies over 4000 lipids. This assay is covering 51 groups of lipids, such as CE, Cer, HexCer, SM, FA, CAR, Eicosanoid, PC, LPC, PE, LPE, PG, LPG, PS, LPS, PI, TG, DG. Quantitative Lipidomics is used in biomedical research, food and animal science, pharmaceutical research, environmental science and many other applications.
Please note the following details of the promotional offer:
A minimum of twelve (12) samples per work order is required. Work orders or quotes must be signed within the promotional period to be eligible for this offer. Only sample types acceptable for TM Widely-Targeted Metabolomics or Quantitative Lipidomics are eligible. See sample requirements for details. This offer cannot be combined with any other offers, promotions, or discounts. The promotional period starts on June 1, 2023, and ends on June 30, 2023. Other conditions apply. Metware Biotechnology, the metabolomics company, reserves the right for final interpretation. Contact us for further details.
More details about our assays’ portfolio (including sample reports) can be found on other pages of this website. And by connecting with us on Twitter and LinkedIn you will always stay updated on our promotional offers, events where you can meet us and new publications on metabolomics, lipidomics and multiomics.